Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2024 Sep 4

PMID 39230827

Authors

Shanshan Wang

Jinglin Miao

Ping Zhu

Li Xu

Affiliations

Soon will be listed here.

Abstract

In this study, we designed a novel formulation based on liposomes for the co-delivery of cancer-derived exosome inhibitor (ketoconazole, Keto) and angiogenesis inhibitor (bevacizumab, mAb). The designed Combo-Lipo formulation was systematically characterized, exhibiting a uniform average particle size of 100 nm, as well as excellent serum and long-term physical stabilities. The cell viability assay revealed that Combo-Lipo treatment significantly reduced the viability of cancer cells compared to free drugs. Moreover, liposomes effectively inhibited angiogenic mediators and reduced tumor immune suppressive factors. The Combo-Lipo formulation demonstrated potent downregulation of angiogenic factors and synergistic effects in suppressing their production. Furthermore, liposomes inhibited tumor-associated macrophages (TAMs), leading to decreased expression of tumor-promoting factors. Together, these findings highlighted the promising characteristics of Combo-Lipo as a therapeutic formulation, including optimal particle size, serum stability, and potent anti-cancer effects, as well as inhibition of angiogenic mediators and TAMs toward treating endometrial cancer.

Citing Articles

Regulation of cancer-associated fibroblasts for enhanced cancer immunotherapy using advanced functional nanomedicines: an updated review.

Liao T, Chen X, Qiu F, Zhang X, Wu F, Zhao Z J Nanobiotechnology. 2025; 23(1):166.

PMID: 40038745 PMC: 11877876. DOI: 10.1186/s12951-025-03217-0.

References

Jabbari N, Akbariazar E, Feqhhi M, Rahbarghazi R, Rezaie J . Breast cancer-derived exosomes: Tumor progression and therapeutic agents. J Cell Physiol. 2020; 235(10):6345-6356. DOI: 10.1002/jcp.29668. View

Tetta C, Ghigo E, Silengo L, Deregibus M, Camussi G . Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine. 2012; 44(1):11-9. PMC: 3726927. DOI: 10.1007/s12020-012-9839-0. View

Thakur A, Parra D, Motallebnejad P, Brocchi M, Chen H . Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact Mater. 2021; 10:281-294. PMC: 8636666. DOI: 10.1016/j.bioactmat.2021.08.029. View

Peinado H, Lavotshkin S, Lyden D . The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21(2):139-46. DOI: 10.1016/j.semcancer.2011.01.002. View

Kalluri R, Zeisberg M . Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401. DOI: 10.1038/nrc1877. View

Rundhaug J . Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9(2):267-85. PMC: 6740080. DOI: 10.1111/j.1582-4934.2005.tb00355.x. View

Yang X, Li Y, Zou L, Zhu Z . Role of Exosomes in Crosstalk Between Cancer-Associated Fibroblasts and Cancer Cells. Front Oncol. 2019; 9:356. PMC: 6510008. DOI: 10.3389/fonc.2019.00356. View

Lim D, Do Y, Kwon B, Chang W, Lee M, Kim J . Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer. BMB Rep. 2020; 53(6):291-298. PMC: 7330806. View

Geindreau M, Bruchard M, Vegran F . Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context. Cancers (Basel). 2022; 14(10). PMC: 9139472. DOI: 10.3390/cancers14102446. View

10.

Cao J, Liu X, Yang Y, Wei B, Li Q, Mao G . Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/ BAI1 signaling pathway. Angiogenesis. 2020; 23(3):325-338. DOI: 10.1007/s10456-020-09707-z. View

11.

Parvathaneni V, Kulkarni N, Muth A, Gupta V . Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019; 24(10):2076-2085. DOI: 10.1016/j.drudis.2019.06.014. View

12.

Zhigaltsev I, Cullis P . Morphological Behavior of Liposomes and Lipid Nanoparticles. Langmuir. 2023; 39(9):3185-3193. DOI: 10.1021/acs.langmuir.2c02794. View

13.

Wang S, Chen Y, Guo J, Huang Q . Liposomes for Tumor Targeted Therapy: A Review. Int J Mol Sci. 2023; 24(3). PMC: 9916501. DOI: 10.3390/ijms24032643. View

14.

Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N . n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis. 2004; 25(12):2303-10. DOI: 10.1093/carcin/bgh265. View

15.

Ghalehbandi S, Yuzugulen J, Pranjol M, Pourgholami M . The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023; 949:175586. DOI: 10.1016/j.ejphar.2023.175586. View

16.

Chen Y, Tan W, Wang C . Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition. Onco Targets Ther. 2018; 11:3817-3826. PMC: 6038883. DOI: 10.2147/OTT.S168317. View

17.

Li W, Chu C, Chen M, Lu Y, Lai J, You B . Lepista sordida Water Extract Enhances the Maturation of Mouse Dendritic Cells in Vitro and in Vivo. Iran J Immunol. 2018; 15(4):256-268. DOI: 10.22034/IJI.2018.39395. View

18.

Kang X, Wang H, Peng H, Chen B, Zhang W, Wu A . Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacol Sin. 2017; 38(6):885-896. PMC: 5520183. DOI: 10.1038/aps.2017.10. View

19.

Mo X, Zheng Z, He Y, Zhong H, Kang X, Shi M . Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. J Control Release. 2018; 287:12-23. DOI: 10.1016/j.jconrel.2018.08.012. View

20.

Bishop E, Bell G, Bloor S, Broom I, Hendry N, Wheatley D . An in vitro model of angiogenesis: basic features. Angiogenesis. 2003; 3(4):335-44. DOI: 10.1023/a:1026546219962. View